Citations

Clear

16 citation(s) found for "Li, Yanfeng".

KIBRA upregulation increases susceptibility to podocyte injury and glomerular disease progression
Meliambro, Kristin, Yang, Yanfeng , Cos, Marina de , Ballestas, Estefania Rodriguez , Malkin, Caroline, Haydak, Jonathan C. , Lee, John R. , Salem, Fadi , Mariani, Laura , Gordon, Ronald E., Basgen, John M. , Wen, Huei Hsun , Fu, Jia , Azeloglu, Evren U. , He, John Cijiang , Wong, Jenny, Salem, Fadi E , He, Cijiang , Campbell, Kirk Nicholas

Mayo Clinic

JCI Insight | February 28, 2023 | Volume: 8 | Issue: 7 | Pages: No page available

10.1172/jci.insight.165002 | PMID 36853804 Get It

Despite recent progress in the identification of mediators of podocyte injury, mechanisms underlying podocyte loss remain poorly understood, and cell-specific therapy is lacking. We previously reported that kidney and brain expressed protein (KIBRA), encoded by WWC1 , promotes podocyte injury in vitro through activation of the Hippo signaling pathway. KIBRA expression is increased in the glomeruli of patients with focal segmental glomerulosclerosis, and KIBRA depletion in vivo is protective against acute podocyte injury. Here, we tested the consequences of transgenic podocyte-specific WWC1 expression in immortalized human podocytes and in mice, and we explored the association between glomerular WWC1 expression and glomerular disease progression. We found that KIBRA overexpression in immortalized human podocytes promoted cytoplasmic localization of Yes-associated protein (YAP), induced actin cytoskeletal reorganization, and altered focal adhesion expression and morphology. WWC1 -transgenic (KIBRA-overexpressing) mice were more susceptible to acute and chronic glomerular injury, with evidence of YAP inhibition in vivo. Of clinical relevance, glomerular WWC1 expression negatively correlated with renal survival among patients with primary glomerular diseases. These findings highlight the importance of KIBRA/YAP signaling to the regulation of podocyte structural integrity and identify KIBRA-mediated injury as a potential target for podocyte-specific therapy in glomerular disease.
The immune dysregulations in inflammatory arthritis immune related adverse events
Zhu, Xingxing , Li, Yanfeng , Jaquith, Jane, McCarthy-Fruin, Kathleen, Thanarajasingam, Uma , Zeng, Hu

Mayo Clinic

The Journal of Immunology | January 2, 2023 | Volume: 208 | Issue: Supplement_1 | Pages: 174.05-174.05

10.4049/jimmunol.208.supp.174.05 Get It

Abstract The immune checkpoint inhibition therapy induces various immune related adverse events (irAEs). The immunological basis of irAEs remains unclear. We recruited a cohort of patients with inflammatory arthritis irAE (IA-irAE), the most common form of rheumatic irAEs, together with matched patients with conventional rheumatoid arthritis (RA) and cancer patients without irAEs. Comprehensive clinical and immunological investigations reveal an imbalance of T cell exhaustion and senescence in IA-irAE patients, and immunological similarities between IA-irAE patients and seronegative RA patients. These data suggest that IA-irAE and seronegative RA may have shared immunological mechanisms. Thus, our study identifies potential immunological underpinnings of IA-irAE and the relationship between IA-irAE and conventional RA. The results may have implications for managing irAE and seronegative RA patients. Supported byR01AR0077518 Arthritis National Research Foundation
mTORC2 contributes to murine lupus associated immunopathology
Zhou, Xian , Li, Yanfeng , Zeng, Hu , Davidson, Anne

Mayo Clinic

The Journal of Immunology | January 2, 2023 | Volume: 208 | Issue: Supplement_1 | Pages: 103.02-103.02

10.4049/jimmunol.208.supp.103.02 Get It

Abstract The development of systemic lupus erythematosus (SLE) is associated with overactivation of the type I interferon (IFN) pathway, lymphopenia, and increased follicular helper T (Tfh) cell differentiation. However, the cellular and molecular mechanisms of action of type I IFN in SLE remains incompletely understood. Here we show that type I IFN activates the mechanistic target of rapamycin complex 2 (mTORC2) in T cells to promote T cell lymphopenia. mTORC2 also promotes Tfh differentiation and disrupts Treg homeostasis. Inactivation of mTORC2 greatly ameliorated the immunopathology in a lupus-prone mouse model, associated with reduced Tfh differentiation, normalization of Treg homeostasis and reduced T cell glucose metabolism. These data indicate that mTORC2 acts downstream of type I IFN and costimulatory receptor ICOS, to promote T cell lymphopenia and Tfh differentiation in murine lupus development, suggesting that inhibition of mTORC2 could limit lupus disease progression. Supported by Lupus Research Alliance Mayo Foundation for Medical Education and Research R01AR077518
mTORC2 contributes to systemic autoimmunity
Qi, Haiyu, Li, Meilu , Li, Yanfeng , Zhu, Xingxing , Amin, Shreyasee , Alexander, Mariam P., Diadhiou, Catherine M.M. , Zeng, Hu , Alexander, Mariam , Zeng, Hu , Zhu, Xingxing , Zhou, Xian , Davidson, Anne

Mayo Clinic

Immunology | October 23, 2022 | Volume: 168 | Issue: 3 | Pages: 554-568

10.1111/imm.13594 | PMID 36273262 Get It

AbstractThe development of many systemic autoimmune diseases, including systemic lupus erythematosus, is associated with overactivation of the type I interferon (IFN) pathway, lymphopenia and increased follicular helper T (Tfh)‐cell differentiation. However, the cellular and molecular mechanisms underlying these immunological perturbations remain incompletely understood. Here, we show that the mechanistic target of rapamycin complex 2 (mTORC2) promotes Tfh differentiation and disrupts Treg homeostasis. Inactivation of mTORC2 in total T cells, but not in Tregs, greatly ameliorated the immunopathology in a systemic autoimmunity mouse model. This was associated with reduced Tfh differentiation, B‐cell activation, and reduced T‐cell glucose metabolism. Finally, we show that type I IFN can synergize with TCR ligation to activate mTORC2 in T cells, which partially contributes to T‐cell lymphopenia. These data indicate that mTORC2 may act as downstream of type I IFN, TCR and costimulatory receptor ICOS, to promote glucose metabolism, Tfh differentiation, and T‐cell lymphopenia, but not to suppress Treg function in systemic autoimmunity. Our results suggest that mTORC2 might be a rational target for systemic autoimmunity treatment.
A Flare Risk Index Informed by Select Immune Mediators in Systemic Lupus Erythematosus
Munroe, Melissa E. , Blankenship, Derek, DeFreese, Daniele C., Purushothaman, Mohan, DeJager, Wade , Macwana, Susan , Guthridge, Joel M. , Kamp, Stan, Redinger, Nancy, Aberle, Teresa, Chakravarty, Eliza F., Arriens, Cristina , Li, Yanfeng , Zeng, Hu , McCarthy-Fruin, Kathleen, Osei‐Onomahm, Shirley‐Ann, Thanarajasingam, Uma , Jupe, Eldon R. , McCarthy-Fruin, Kathleen A, James, Judith A , Zeng, Hu , Guthridge, Joel M , James, Judith A.

Mayo Clinic

Arthritis & Rheumatology | October 17, 2022 | Volume: 75 | Issue: 5 | Pages: 723-735

10.1002/art.42389 | PMID 36245261 Get It

ObjectiveSystemic lupus erythematosus (SLE) is marked by immune dysregulation linked to varied clinical disease activity. Using a unique longitudinal cohort of SLE patients, this study sought to identify optimal immune mediators informing an empirically refined flare risk index (FRI) reflecting altered immunity prior to clinical disease flare.MethodsThirty‐seven SLE‐associated plasma mediators were evaluated by microfluidic immunoassay in 46 samples obtained in SLE patients with an imminent clinical disease flare (preflare) and 53 samples obtained in SLE patients without a flare over a corresponding period (pre‐nonflare). SLE patients were selected from a unique longitudinal cohort of 106 patients with classified SLE (meeting the American College of Rheumatology 1997 revised criteria for SLE or the Systemic Lupus International Collaborating Clinics 2012 revised criteria for SLE). Autoantibody specificities, hybrid SLE Disease Activity Index (hSLEDAI) scores, clinical features, and medication usage were also compared at preflare (mean ± SD 111 ± 47 days prior to flare) versus pre‐nonflare (99 ± 21 days prior to nonflare) time points. Variable importance was determined by random forest analysis with logistic regression subsequently applied to determine the optimal number and type of analytes informing a refined FRI.ResultsPreflare versus pre‐nonflare differences were not associated with demographics, autoantibody specificities, hSLEDAI scores, clinical features, nor medication usage. Forward selection and backward elimination of mediators ranked by variable importance resulted in 17 plasma mediator candidates differentiating preflare from pre‐nonflare visits. A final combination of 11 mediators best informed a newly refined FRI, which achieved a maximum sensitivity of 97% and maximum specificity of 98% after applying decision curve analysis to define low, medium, and high FRI scores.ConclusionWe verified altered immune mediators associated with imminent disease flare, and a subset of these mediators improved the FRI to identify SLE patients at risk of imminent flare. This molecularly informed, proactive management approach could be critical in prospective clinical trials and the clinical management of lupus.
Fine‐scale mapping of 8q24 locus identifies multiple independent risk variants for breast cancer
Shi, Jiajun , Zhang, Yanfeng , Zheng, Wei , Michailidou, Kyriaki , Ghoussaini, Maya , Bolla, Manjeet K. , Wang, Qin, Beesley, Jonathan, Kar, Siddhartha , Andrulis, Irene L. , Beckmann, Matthias W. , Zhao, Zhiguo , Benı́tez, Javier , Beeghly‐Fadiel, Alicia, Blot, William J. , Bogdanova, Natalia , Bojesen, Stig E. , Brauch, Hiltrud , Brenner, Hermann , Brinton, Louise A. , Brüning, Thomas , Burwinkel, Barbara , Cai, Hui , Canisius, Sander , Chang‐Claude, Jenny , Choi, Ji‐Yeob , Couch, Fergus J. , Darabi, Hatef, Devilee, Peter , Droit, Arnaud , Dörk, Thilo , Fasching, Peter A. , Fletcher, Olivia , Flyger, Henrik, Fostira, Florentia, Gaborieau, Valérie , García‐Closas, Montserrat , Giles, Graham G. , Grip, Mervi, Guénel, Pascal , Haiman, Christopher A., Hamann, Ute, Hartman, Mikael , Miao, Hui , Hopper, John L. , Hsiung, Chia‐Ni , Investigators, kConFab, Jakubowska, Anna , Johnson, Nichola , Torres, Diana , Kabisch, Maria, Kang, Daehee , Khan, Sofia , Knight, Julia A. , Kosma, Veli‐Matti, Lambrechts, Diether , Li, Jingmei , Lindblom, Annika , Lubiński, Jan , Mannermaa, Arto, Manoukian, Siranoush , Margolin, Sara , Matsuo, Keitaro , McLean, Catriona , Meindl, Alfons, Børresen‐Dale, Anne‐Lise , Orr, Nick , Ouweland, Ans M.W. van den, Peterlongo, Paolo , Putti, Thomas Choudary , Sangrajrang, Suleeporn , Sawyer, Elinor J. , Schmidt, Marjanka K. , Schmutzler, Rita K., Shen, Chen‐Yang , Hou, Ming‐Feng , Shrubsole, Matha J., Southey, Melissa C. , Swerdlow, Anthony J. , Teo, Soo‐Hwang , Thienpont, Bernard , Tollenaar, Robert A.E.M., Tomlinson, Ian , Truong, Thérèse , Tseng, Chiu-Chen , Wen, Wanqing , Winqvist, Robert , Wu, Anna H. , Yip, Cheng Har , Zheng, Ying , Floris, Giuseppe , Cheng, Ching‐Yu , Hooning, Maartje J. , Seynaeve, Caroline, Kristensen, Vessela N., Simard, Jacques , Chenevix‐Trench, Georgia , Dunning, Alison M. , Antoniou, Antonis C. , Easton, Douglas F. , Long, Jirong , Durocher, Francine , Thorne, Heather , Shrubsole, Martha J. , Lambrechts, Diether , Wang, Qin, Dennis, Joe , Lush, Michael J. , Milne, Roger L. , Shu, Xiao‐Ou , Anton‐Culver, Hoda , Arndt, Volker , Guo, Xingyi , Beeghly‐Fadiel, Alicia , Broeks, Annegien , Couch, Fergus J. , Cox, Angela , Cross, Simon S. , Czene, Kamila , Hollestelle, Antoinette , Investigators, kConFab, Ito, Hidemi , Lophatananon, Artitaya , Mannermaa, Arto , Marchand, Loı̈c Le , Marmé, Frederik , Meindl, Alfons, Muir, Kenneth , Neuhausen, Susan L. , Nevanlinna, Heli , Nord, Silje , Olson, Janet E. , Rudolph, Anja , Toland, Amanda Ewart , Zamora, Pilar M. , Hooning, Maartje J. , Martens, John W.M. , Kristensen, Vessela N. , Hall, Per N , Pharoah, Paul D.P. , Cai, Qiuyin , Dörk, Thilo , Lambrechts, Diether , Giles, Graham G , Peterlongo, Paolo , Teo, Soo H , Shrubsole, Martha J , Swerdlow, Anthony J , Southey, Melissa C , Matsuo, Keitaro , Dunning, Alison M , Jakubowska, Anna , Lambrechts, Diether , Brenner, Hermann , Guénel, Pascal , Hartman, Mikael , Li, Jingmei , Torres, Diana , García-Closas, Montserrat , Schmidt, Marjanka K , Michailidou, Kyriaki , Bogdanova, Natalia V , Benitez, Javier , Simard, Jacques , Chenevix-Trench, Georgia , Zheng, Wei , Kar, Siddhartha , Devilee, Peter , Manoukian, Siranoush , Lubinski, Jan , Fletcher, Olivia , Bojesen, Stig E , Truong, Therese , Mclean, Catriona , Brauch, Hiltrud , Lindblom, Annika , Sawyer, Elinor J , Orr, Nick , Kang, Daehee , Droit, Arnaud

Mayo Clinic

International Journal of Cancer | April 18, 2016 | Volume: 139 | Issue: 6 | Pages: 1303-1317

10.1002/ijc.30150 | PMID 27087578 Get It

Previous genome‐wide association studies among women of European ancestry identified two independent breast cancer susceptibility loci represented by single nucleotide polymorphisms (SNPs) rs13281615 and rs11780156 at 8q24. A fine‐mapping study across 2.06 Mb (chr8:127,561,724–129,624,067, hg19) in 55,540 breast cancer cases and 51,168 controls within the Breast Cancer Association Consortium was conducted. Three additional independent association signals in women of European ancestry, represented by rs35961416 (OR = 0.95, 95% CI = 0.93–0.97, conditional p = 5.8 × 10−6), rs7815245 (OR = 0.94, 95% CI = 0.91–0.96, conditional p = 1.1 × 10−6) and rs2033101 (OR = 1.05, 95% CI = 1.02–1.07, conditional p = 1.1 × 10−4) were found. Integrative analysis using functional genomic data from the Roadmap Epigenomics, the Encyclopedia of DNA Elements project, the Cancer Genome Atlas and other public resources implied that SNPs rs7815245 in Signal 3, and rs1121948 in Signal 5 (in linkage disequilibrium with rs11780156, r2 = 0.77), were putatively functional variants for two of the five independent association signals. The results highlighted multiple 8q24 variants associated with breast cancer susceptibility in women of European ancestry.